Pulse Biosciences, Inc · NASDAQ:PLSE
Pulse Biosciences — Investor Presentation (March 2026)
16 slides from Pulse Biosciences's investor presentation, Mar 3, 2026
Slide 1: Corporate Overview March 2026
(@) Pulse Biosciences’ Corporate Overview March 2026
Slide 2: Forward Looking Statements
Forward Looking Statements (© PuseBioscences All statements inthis presentation that are not historical are forwordookng statements, including, among other things, ‘statements relating to the effectiveness of the Company's Nanosecond Pulsed Feld Ablation (nsPFA) technology and ‘Pulse™ System to nont
Slide 3: Our Mission
Our Mission To build a viable Company that designs, produces, and commercializes nano- pulse technology to improve and extend the lives of patients. To solve the needs of patients, physicians, and healthcare providers with high quality and high reliability products and services, developed in accorda
Slide 4: Experienced Technologists, Operators and Clinicians
Experienced Technologists, Operators and Clinicians From Proven Leadership Team Renowned Scientific Expertise a Dr. NivAd fa Dr. Gan Dunnington Ee Dr. David Ker Established Board of Directors Robert (Bob) W. Duggan erg ey Bichara £2. van den Brock $B Director D ruse Biosciences
Slide 5: Financial & Strategic Snapshot
Financial & Strategic Snapshot - Balance sheet as of 12/31/2025 + Cash and cash equivalents balance of $80.7mm + Nodebt + Cash used in operating activities of $54.1mm in 2025 ~75% + Cash burn increasing: Strategic Capital to support Insider significant clinical opportunities ($14.8mm of cash used Ow
Slide 6: The Nanosecond PFA Advantage - Novel Mechanism, Deeper Ablation
The Nanosecond PFA Advantage - Novel Mechanism, Deeper Ablation cient ablation mechanism, ~ High Thermal Energy + Point to point ablation + Destroys all tissue - Thermal spread risk (© putseBlosciences First Gen PFA vow ww Lit a + Long-duration weak pulses physically destroy cell membranes + Thermal
Slide 7: Pioneering nPulse Technology
Pioneering nPulse™ Technology Creating broad and in-depth IP portfolio to effectively own the Nanosecond PFA space PATENT PORTFOLIO 250+ Globally owned or ticensed Covering nPulse energy from end-to-end, from generator to electrodes, designed for Generator and System Seems § ultra-short high-energy
Slide 8: EP Market Opportunity
EP Market Opportunity AF Ablation Drivers for Pulse in the EP AF Ablation Market + Drop-in workflow replacement Speed + efficien cy over all prior PFA devices Enhanced lesion quality Elevated safety Pulse Biosciences: nPulse™ technology upends the EP market with a differentiated energy and novel des
Slide 9: nsPFA Unlocks New Potential in EP
nsPFA Unlocks New Potential in EP yy 2) = YY FESION + NANOPULSE-AF IDE QUALITY SPEED WORKFLOW EFFICACY approval + single + Fewer taster +Mapandablate- Durability circumferential applications: single catheter preaeis + Expect to fully enroll IDE lesion = mon in 2026 sTotalPVispeed ——« Conscious ve ao
Slide 10: nsPFA Catheter
nsPFA Catheter Pulmonary Vein Isolation Workflow Ostial PF. wa * Two Applications per Pulmonary Vein + Single ostial application + Single antral application a4 a Ae + Depending on Anatomy + Single anterior carina applications on each side fAntral PF Application "3 ) + Potential additional right-side
Slide 11: nsPFA FIH Trial: Procedure Time and Freedom AF/AFL/AT Success Rate
nsPFA FIH Trial: Procedure Time and Freedom AF/AFL/AT Success Rate cn i) en eum sat nat selesne sas esenana4soee rasae nsec Pte some) encom osu geen cw Hanan) wmnourm moana (O PusseBioscences tou _ Freedom om AF/AFL/AT Tine ater inl baton ents Clinical Roadmap + Additional data - accepted as late br
Slide 12: Next Gen nPulse Cardiac Catheter - Development Stage
Next Gen nPulse Cardiac Catheter - Development Stage » Enables Single Catheter Workflow: building on the platform to enable Pulmonary Vein Isolation / Posterior Wall Isolation and Mitral lsthmus / Cavotricuspid Isthmus lines with switchable electrodes + Combines the circumferential rings with a larg
Slide 13: Pulse Biosciences' nPulse Platform
Pulse Biosciences’ nPulse™ Platform . Opportunity for expansion Multiple p into multiple markets with Opportunities Beyond EP billion dollar plus TAMS a U.S. Addressable Global ‘Annual Market Potential Market Cardiac Surgery $1.8B° $6.0B" = NANOCLAMP-AF Pivotal Study Eni Thyroid Application - Market
Slide 14: 2026 Plans
2026 Plans Electrophysiology * Clear safety, speed, workflow, and durability evidence continues to expand * Industry leading efficacy evidence continues to evolve * Complete NANOPULSE AF IDE enrollment * Continued release of clinical data (Heart Rhythm Society 2026) + Progression of Next Generation
Slide 15: Summary
Summary Novel nPulse” Energy + Unique Mechanism of Action + Patent protected + Nonthermal Target Market Values + +$3B U.S. annual addressable market in EP * Additional opportunities with +$1B markets (D PutseBiosciences IP 250+ Owned or Licensed Patents * Pulse effectively owns the Nanosecond PFA Sp
Slide 16: Citations
Citations 4 5) Clarivate - US EP Market Report. Data on File. ‘Company filings, BofA Global Research. Revenue is BofA estimate from BofA Global Research Market Report. Data on File. Joglar et al JA.C.C.VOL.83,NO.1,20242023 Guideline for the Diagnosis and Management of Atrial Fibrillation JAN U ARY2/
Pulse Biosciences — Investor Presentation (March 2026) on 6ix